Atlas Trials

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Clinical trial NCT07108387 · RECRUITING

Trial details

NCT number
NCT07108387
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Giant Cell Arteritis (GCA)
Start date
2026-01-05
Primary completion
2027-06-11
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.